Legal Representation
Attorney
Jonathan M. Rixen
USPTO Deadlines
Next Deadline
1859 days remaining
Section 71 Declaration Due (Principal Register 66a) (Based on registration date 20250128)
Due Date
January 28, 2031
Grace Period Ends
July 28, 2031
Additional deadlines exist. Contact your attorney for complete deadline information.
Application History
26 events| Date | Code | Type | Description | Documents |
|---|---|---|---|---|
| Sep 12, 2025 | OPNX | P | NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB | Loading... |
| Sep 5, 2025 | FINO | P | FINAL DECISION TRANSACTION PROCESSED BY IB | Loading... |
| Aug 29, 2025 | CRCV | M | CORRECTION TRANSACTION RECEIVED FROM IB | Loading... |
| Aug 27, 2025 | OPNS | P | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | Loading... |
| Aug 27, 2025 | OPNR | P | NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB | Loading... |
| Aug 15, 2025 | FICS | P | FINAL DISPOSITION NOTICE SENT TO IB | Loading... |
| Aug 15, 2025 | FIMP | P | FINAL DISPOSITION PROCESSED | Loading... |
| Apr 29, 2025 | FICR | P | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | Loading... |
| Jan 28, 2025 | NRCC | E | NOTICE OF REGISTRATION CONFIRMATION EMAILED | Loading... |
| Jan 28, 2025 | R.PR | A | REGISTERED-PRINCIPAL REGISTER | Loading... |
| Dec 10, 2024 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | Loading... |
| Dec 10, 2024 | PUBO | A | PUBLISHED FOR OPPOSITION | Loading... |
| Dec 4, 2024 | NONP | E | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | Loading... |
| Nov 18, 2024 | CNSA | O | APPROVED FOR PUB - PRINCIPAL REGISTER | Loading... |
| Nov 17, 2024 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED | Loading... |
| Nov 17, 2024 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE | Loading... |
| Nov 17, 2024 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED | Loading... |
| Aug 11, 2024 | RFNT | P | REFUSAL PROCESSED BY IB | Loading... |
| Jul 24, 2024 | RFCS | P | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | Loading... |
| Jul 24, 2024 | RFRR | P | REFUSAL PROCESSED BY MPU | Loading... |
| Jun 28, 2024 | RFCR | E | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | Loading... |
| Jun 27, 2024 | CNRT | R | NON-FINAL ACTION WRITTEN | Loading... |
| Jun 17, 2024 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
| Apr 5, 2024 | MAFR | O | APPLICATION FILING RECEIPT MAILED | Loading... |
| Apr 1, 2024 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | Loading... |
| Mar 28, 2024 | REPR | M | SN ASSIGNED FOR SECT 66A APPL FROM IB | Loading... |
Detailed Classifications
Class 001
Chemical reagents, other than for medical or veterinary purposes; biological preparations for use in industry and science, other than for medical or veterinary purposes; diagnostic preparations for scientific use, other than for medical or veterinary purposes; test paper, chemical; chemical preparations for scientific purposes, other than for medical or veterinary use; biochemicals preparations for scientific use; chemical substances for analyses in laboratories for scientific use, other than for medical or veterinary purposes; reagent paper, other than for medical or veterinary purpose; biological preparations for cell culture, other than for medical or veterinary use; diagnostic reagents and preparations for scientific use except for medical and veterinary use; active chemical ingredients for use in the manufacture of pharmaceuticals for treating tumors, asthma, arthritis, viral diseases, respiratory diseases, inflammation, fibrosis, hypertension, hyperlipidemia, cardiovascular diseases, eye diseases, angina, diabetes, and insomnia
Class 005
Medicines for human purposes for treating tumors, asthma, arthritis, viral diseases, respiratory diseases, inflammation, fibrosis, hypertension, hyperlipidemia, cardiovascular diseases, eye diseases, angina, diabetes, and insomnia; biochemical medicines for the treatment of tumors, asthma, arthritis, viral diseases, respiratory diseases, inflammation, fibrosis, hypertension, hyperlipidemia, cardiovascular diseases, eye diseases, angina, diabetes, and insomnia; pharmaceutical preparations for the treatment of tumors, asthma, arthritis, viral diseases, respiratory diseases, inflammation, fibrosis, hypertension, hyperlipidemia, cardiovascular diseases, eye diseases, angina, diabetes, and insomnia; chemical reagents for medical and veterinary purposes; biological preparations for medical purposes for treating tumors, asthma, arthritis, viral diseases, respiratory diseases, inflammation, fibrosis, hypertension, hyperlipidemia, cardiovascular diseases, eye diseases, angina, diabetes, and insomnia; reagent paper for medical purposes; drugs for medical purposes for treating tumors, asthma, arthritis, viral diseases, respiratory diseases, inflammation, fibrosis, hypertension, hyperlipidemia, cardiovascular diseases, eye diseases, angina, diabetes, and insomnia; diagnostic preparations for medical purposes; vaccines
Class 042
Scientific development and research services in the field of drugs; vaccine research and development services; scientific research and development of new products for others; scientific research; research of biochemistry; biotechnology research; pharmaceutical drug research; development services in the field of pharmaceutical drugs; medical research service; biomedical research services
Additional Information
Pseudo Mark
GAI PET
Classification
International Classes
001
005
042